Amarin Corp ADR (AMRN)
$0.60
0.00 (0.00%)
AMRN Stock Quote Delayed 30 Minutes
3 Big Stock Charts for Tuesday: Amarin, Campbell Soup, and Church & Dwight
Tuesday's big stock charts feature three big winners in Monday's big rally — all of which have hopes for further upside ahead.
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
243.02M
PE Ratio
-6.63
EPS
-0.09
Volume (Avg. Vol.)
Day's Range
-
52-Week Range
$0.57 - $1.37
Dividend & Yield
N/A (N/A)
AMRN Stock Predictions, Articles, and Amarin Corp ADR News
Even Though It’s Risky, Amarin Stock Is a Worthwhile Buy
I’d expect based on Q3 2019 that the company will report strong revenue growth in the fourth quarter, but the real show will come in Q2 2020 and onward as Amarin's expanded salesforce meets with doctors across the country.
First-Mover Advantage Will Benefit Amarin Stock More Than You Think
There’s no reason Amarin stock won’t become a big success with Vascepa, especially with access to millions of patients.
Why Amarin Stock Is Getting No Love Early in 2020
Despite substantial attention on Amarin stock due to the underlying company’s Vascepa drug receiving FDA approval, shares haven’t looked great in 2020. Is this a discounted opportunity or a sign to stay away?
Positive Catalysts Make Amarin Stock a Buy on Current Weakness
As AMRN stock's future will likely depend on how strong sales of Vascepa will be, investors may want to wait for the upcoming Q4 numbers before investing in Amarin shares.
Vascepa Growth Will Power Amarin Stock Way Higher in 2020
Vascepa's growth trajectory will sustain robust momentum in 2020, and as it does, Amarin stock will stay in rally mode.
Risks Remain, but Amarin Stock Is a Buy at Today’s Prices
Also, the courts could rule against Amarin's favor in the patent suit. Yet, with material upside potential, Amarin stock could be worth the risk.
Amarin’s Vascepa Is a Great Story Filled With Too Many Unknowns
The biggest unknown weighing on Amarin stock is how long the decision to take Vascepa will be up to patients, rather than experts.
Bears Are Now in Control of Amarin Stock, But Not for Long
Bears are in control of Amarin stock, and selling pressure has driven the price down. But Vascepa will drive huge success for Amarin in 2020.
Does the Recent Amarin Stock Pullback Put Shares in the Buy Category?
Amarin stock is struggling, and that's been the case even before the stock market pulled back. Here's how AMRN looks now.
Consider Adding Amarin to Your Portfolio as Its Competition Falters
Investors should feel confident adding Amarin stock to their portfolios, especially because it has the government on its side.
Amarin Stock Will Deliver More Upside for Patient Investors
As Vascepa's competition dwindles and the drug gains market share, AMRN stock could be in for some significant upside in 2020.
Amarin Stock Projections Are Based on Hype and Hope
Amarin stock has some potential, but there are also many risks involved. Therefore, it doesn’t hurt to wait if you really want to buy these shares.
Amarin Stock is Still Fully Valued Despite All the Good News
AMRN stock is likely fairly priced -- possibly even overpriced -- right now. It might take more time before analysts and the company actually raise their revenue and cash flow estimates based on patient uptake of Vascepa.
It’s Time to Go Long Amarin Stock After Recent Headlines
AstraZeneca out of the way. Plus, some key technical resistance is also dismantled, so it’s time to go long AMRN stock today.
Why Amarin Stock Is Poised for a Healthy 2020
During the past year, Amarin stock has been a laggard. But this could change in 2020 with the company's new drug poised for long-term growth.
After FDA Approval, Amarin Stock Is Stuck in Worrisome Trading
Amarin stock has faded in recent weeks despite a spate of good news. That response suggests AMRN shares may have further to fall.
AstraZeneca’s Loss is Amarin’s Big Gain This Year
AstraZeneca is stopping a large clinical study of its fish-oil-derived heart drug, Epanova. That’s good news for Amarin and Amarin stock.
Amarin Stock Bouncing Back After Revised Results and 2020 Guidance
Amarin stock is set for growth with Vascepa approval and sales outlook for 2020 predicting revenue will eventually hit billions of dollars
